Related Experiment Video
Updated: Feb 19, 2026
A Battery of Motor Tests in a Neonatal Mouse Model of Cerebral Palsy
Published on: November 3, 2016
[Spinal muscular atrophy : Time for newborn screening?]
K Vill1, A Blaschek2, U Schara3
1Abteilung für Neuropädiatrie, Entwicklungsneurologie und Sozialpädiatrie, Zentrum für neuromuskuläre Erkrankungen und Neuroimmunologie im Kindesalter, LMU Zentrum - iSPZ Hauner, Kinderklinik und Kinderpoliklinik, Dr. von Haunersches Kinderspital der Universität München, Lindwurmstraße 4, 80337, München, Deutschland. Katharina.vill@med.uni-muenchen.de.
Spinal muscular atrophy (SMA) is a severe childhood neurodegenerative disease. Early detection and presymptomatic treatment are crucial for improving outcomes, with newborn screening being a key goal.
Area of Science:
- Pediatric Neurology
- Genetics
- Neurodegenerative Diseases
Background:
- Spinal muscular atrophy (SMA) is the most common fatal childhood neurodegenerative disease.
- Severe infantile SMA (type 1) accounts for 60% of cases, often leading to death within 18 months without intervention.
- Recent advancements have progressed from theoretical concepts to clinical trials, resulting in the first approved pharmacological treatment for SMA.
Purpose of the Study:
- To highlight the critical role of early detection in the success of new SMA therapies.
- To emphasize the benefits of initiating treatment before symptom onset for improved patient outcomes.
- To discuss the feasibility and importance of presymptomatic diagnosis through molecular genetic newborn screening.
Main Methods:
- Review of current therapeutic approaches and clinical trial data for SMA.
- Analysis of the impact of treatment timing on patient outcomes.
- Evaluation of the technical and ethical considerations for implementing newborn screening for SMA.
Main Results:
- Pharmacological treatment for SMA has been approved for the first time.
- Early treatment initiation, ideally before symptom onset, significantly improves outcomes compared to delayed treatment.
- Presymptomatic diagnosis is essential to initiate treatment before irreversible motor neuron degeneration.
Conclusions:
- Early detection is paramount for effective SMA therapy.
- Initiating treatment prior to symptom onset offers the best chance for improved outcomes.
- Molecular genetic newborn screening presents a viable strategy for achieving presymptomatic diagnosis and timely intervention in SMA.
